Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Davita Inc (DVA) vs Wix.Com Ltd (WIX) Price & Performance

Davita IncTrade
Wix.Com LtdTrade

Price performance (Past 24H)

Key statistics

Davita Inc vs Wix.Com Ltd — how do they compare? Davita Inc trades at $227.08 (market cap $14.92B), while Wix.Com Ltd trades at $53.96 (market cap $2.21B). The key difference: Davita Inc is far larger — about 6.8× Wix.Com Ltd's market cap, and Davita Inc is trading nearer its 52-week high, Wix.Com Ltd nearer its low. Which is the better fit depends on your goals.

DVAWIX
Market Cap
$14.92B$2.21B
Sector
HealthTechnology
52-Week High
$235.71$184.24
52-Week Low
$103.87$40.43
Enterprise Value
$27.47B$1.77B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Davita Inc

DaVita (DVA) trades at $235.58, up 1.19% on the day, near its pivot point of $236. The stock shows a bullish technical trend with strong moving average signals, though RSI levels suggest potential overbought conditions. Fundamentally, revenue grew to $13.64B in 2025, but net income margin dipped to 5.65%. Recent earnings beat expectations in Q4 2025 and Q1 2026, while Q3 2025 missed. Analyst sentiment is mixed with a consensus price target of $231.80, slightly below the current price.

The outlook for DVA is cautiously optimistic, supported by steady revenue growth and expansion in kidney care services. Key risks include high debt levels, with debt-to-asset ratio rising to 65.55% in 2025, and margin pressure from rising costs. Investment opportunity lies in continued execution of value-based care programs and AI-driven efficiency gains, but investors should monitor debt management and regulatory changes in healthcare reimbursement.

Wix.Com Ltd

Wix trades at $52.41, up 4.53% today, with a bullish technical signal from moving averages but overbought RSI readings. Revenue grew to $1.99B in 2025, though net income fell to $50.65M, and the stock carries a high P/E of 62.84. Recent news highlights AI-related volatility and a partnership with Elavon to enhance small business payments.

The outlook is mixed: strong analyst consensus (67.5% buy ratings) and a $83.13 price target suggest upside, but risks include legal investigations, expense spikes, and negative shareholder equity. Earnings misses in Q1 2026 and high valuation metrics warrant caution despite growth potential.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Davita Inc

DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.

Read more on DVA

About Wix.Com Ltd

Wix.com Ltd is a cloud-based development platform provider for millions of registered users worldwide. The company is engaged in web development and management that provides an easy-to-use powerful cloud-based platform of products through a freemium model. Its core products consist of three web editors: the Wix Editor, intended for users with basic technological skills, Wix ADI, intended for novice users and Corvid, intended for more tech-savvy users. The company's web development technology is built based on HTML5 and offers HTML5 compatible capabilities, web design and layout tools, domain hosting, and other marketing and workflow management applications and services. The geographic segments include North America, Europe, Latin America, Asia and others.

Read more on WIX